Xycrobe technology targets certain skin conditions and cosmetic treatments using an isolated, living strain of skin-relevant bacteria, according to Crown, the fast-growing skin health company headquartered in Johnson City, TN.
Xycrobe technology harnesses the power of a particular strain of Cutibacterium acnes subspecies defendens (C. acnes defendens), a subspecies of the most prolific skin-specific bacterial species, which accounts on average for 89% of the bacteria in the sebaceous skin follicles, to improve the health and appearance of the skin by curating and supporting the right strain within the existing microbiome.
The results of the recently published study demonstrate that the Crown’s Biojuve regimen, which incorporates the Xycrobe strain as well as its ferment, supports a healthy skin environment, promotes increased skin hydration, decreases redness, regulates sebum production and reduces the appearance of signs of aging such as fine lines and photodamage.
Biojuve is a new dermatologist dispensed product regimen currently in soft-launch now. The range is expected out in 2023 and will be sold by the Crown Aesthetics team in the US, according to company officials.
“The research we present in this paper debunks numerous myths that have perpetuated for the last half century or so about what constitutes a healthy skin microbiome, what role C. acnes strains play in skin health, and the ability to formulate progressive topicals with live microbes that might contribute to a healthier skin biome overall,” said Dr. Thomas M. Hitchcock, PhD, chief science officer, Crown Laboratories Inc. “We firmly believe that Crown Laboratories Inc. is pioneering the “skin biome care” category with our extensive research into the skin biome. We aim to continue to invest in exploring the relationship between the microbes that live on and in the skin, and how this new philosophy of formulating topicals to holistically consider the skin biome may change how we care for the skin.”
“Traditionally, the medical focus for topical skincare products has always been placed on how any given ingredient may impact the overall health of skin cells with minimal consideration of how the ingredients impact the skin’s microflora, or microbiome,” added Dr. Doris Day, Board Certified Dermatologist and participant in the research study. “The proven efficacy of this patented Xycrobe technology reinforces the idea that the human body depends on symbiosis. I anticipate this research will diversify the way in which doctors address the health and treatment of skin conditions.”
Subjects in this eight-week study used a 5 or 7 point Likert-scale (agree/neither/disagree) over a two month evaluation period. Agreement responses at the 90th percentile or higher included (improved) skin texture, tone, healthy, natural appearance, felt conditioned, radiant, and vibrant (n=121*).
The full study on the effectiveness of Xycrobe along with the findings has been made available to the public.